NCT00416403View on ClinicalTrials.gov

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

June 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

fluvastatin sodium

Given orally

PROCEDURE

Breast Cancer Surgery Only - Arm III

Breast Cancer Surgery

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

60637-1470

University of Chicago Cancer Research Center, Chicago

02115-6084

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00416403 - Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer | Biotech Hunter | Biotech Hunter